**EXCEPTIONAL GROWTH, EXCEPTIONAL YEAR**

**FOURTH-QUARTER AND FULL-YEAR 2020 FINANCIAL RESULTS**

- **SALES PERFORMANCE ACROSS ABBOTT**
  - **$10.7 billion** sales worldwide
  - **+$28.4%** on organic basis

- **FULL-YEAR 2020**
  - **$34.6 billion** sales worldwide
  - **+$9.8%** on organic basis

**FULL-YEAR 2021 GUIDANCE**

- **ADJUSTED DILUTED EPS VS PRIOR YEAR**
  - Reflecting growth of at least 35%
  - At least $5.00

**PIPELINE ADVANCES ACROSS OUR DIVERSE BUSINESSES IN 2020**

**MARKET EXPANSION WITH KEY APPROVALS**
- Expanded Medicare (CMS) reimbursement for MitraClip®, significantly increasing insurance coverage
- FDA approval for HeartMate 3™ heart pump for pediatric patients battling advanced heart failure

**FIRST RAPID HANDHELD BLOOD TEST FOR CONCUSSIONS**
- FDA clearance for 15-minute blood test to help evaluate mild traumatic brain injury, commonly known as concussion

**NEW PEDIALYTE PRODUCTS**
- Expanded Pedialyte® product portfolio with four new products: Pedialyte with Immune Support, Pedialyte Sport, Pedialyte Organic and Pedialyte Electrolyte Water with Zero Sugar

**INNOVATION FOR ACCESS**
- New product launches: FDA clearance for FreeStyle® Libre 2† for adults and kids 4+, CE Mark for FreeStyle Libre 3, CE Mark for FreeStyle Libre 3 and Libre Sense Glucose Sport Biosensor
- Announced long-term support for American Diabetes Association health equity initiative to advance access to care and technology for underserved diabetes communities

**NEUROMODULATION**
- Remotely connecting doctors and patients
  - NeuroSphere™ myPath™ digital health app will allow chronic pain patients to track, analyze and report pain relief and general well-being associated with therapy during neurostimulation trial period
  - App connects patients to physicians with real-time data access

---


1. On a GAAP basis, fourth-quarter Abbott sales increased 28.7%.
2. On a GAAP basis, full-year Abbott sales increased 8.5%.
3. Abbott projects full-year 2021 diluted earnings per share from continuing operations under GAAP of at least $3.74, reflecting growth of at least 50% versus the prior year. Abbott forecasts specified items for the full-year 2021 of $1.26 primarily related to intangible amortization, expenses associated with acquisitions, restructuring and cost reduction initiatives and other net expenses.

† Find important safety information about the FreeStyle Libre portfolio: www.freestylelibre.us/safety-information.

**FORWARD-LOOKING STATEMENTS**

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties, including the impact of the COVID-19 pandemic on Abbott’s operations and financial results, that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended Dec. 31, 2019 and in Item 1A, “Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.